Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review

1 of 5

FEATURED COMPANIES

  • Lannett Company Inc
  • Napp Pharmaceuticals Ltd
  • Sandoz International GmbH
  • MORE
Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and Rest of the World (ROW). Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc Key Recent Developments

Mar 14, 2018: Hikma reports 2017 full year results
Feb 20, 2018: Sigurdur Olafsson appointed Chief Executive Officer of Hikma
Feb 06, 2018: West-Ward Pharmaceuticals Strengthens US Leadership and appoints Daniel Motto as Executive Vice President of US Injectables
Jan 15, 2018: Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific Officer and Global Head of R&D
Aug 17, 2017: Hikma Delivers Stable Profitability and Strong Cash Generation In H1 and Maintains a Solid Balance Sheet

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Lannett Company Inc
  • Napp Pharmaceuticals Ltd
  • Sandoz International GmbH
  • MORE
Section 1 - About the Company
  • Hikma Pharmaceuticals Plc - Key Facts
  • Hikma Pharmaceuticals Plc - Key Employees
  • Hikma Pharmaceuticals Plc - Key Employee Biographies
  • Hikma Pharmaceuticals Plc - Major Products and Services
  • Hikma Pharmaceuticals Plc - History
  • Hikma Pharmaceuticals Plc - Company Statement
  • Hikma Pharmaceuticals Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Hikma Pharmaceuticals Plc - Business Description
  • Business Segment: Branded
  • Overview
  • Performance
  • Business Segment: Generics
  • Overview
  • Performance
  • Business Segment: Injectables
  • Overview
  • Performance
  • Geographical Segment: Europe and ROW
  • Performance
  • Geographical Segment: MENA
  • Performance
  • Geographical Segment: The UK
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Hikma Pharmaceuticals Plc - Corporate Strategy
  • Hikma Pharmaceuticals Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Hikma Pharmaceuticals Plc - Strengths
  • Hikma Pharmaceuticals Plc - Weaknesses
  • Hikma Pharmaceuticals Plc - Opportunities
  • Hikma Pharmaceuticals Plc - Threats
  • Hikma Pharmaceuticals Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Hikma Pharmaceuticals Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 14, 2018: Hikma reports 2017 full year results
  • Feb 20, 2018: Sigurdur Olafsson appointed Chief Executive Officer of Hikma
  • Feb 06, 2018: West-Ward Pharmaceuticals Strengthens US Leadership and appoints Daniel Motto as Executive Vice President of US Injectables
  • Jan 15, 2018: Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific Officer and Global Head of R&D
  • Aug 17, 2017: Hikma Delivers Stable Profitability and Strong Cash Generation In H1 and Maintains a Solid Balance Sheet
  • Jun 26, 2017: Hikma Pharmaceuticals Announces Leadership and Organisational Changes to US Business
  • May 03, 2017: Hikma Changes Registered Office
  • Mar 15, 2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Hikma Pharmaceuticals Plc, Key Facts
  • Hikma Pharmaceuticals Plc, Key Employees
  • Hikma Pharmaceuticals Plc, Key Employee Biographies
  • Hikma Pharmaceuticals Plc, Major Products and Services
  • Hikma Pharmaceuticals Plc, History
  • Hikma Pharmaceuticals Plc, Subsidiaries
  • Hikma Pharmaceuticals Plc, Joint Venture
  • Hikma Pharmaceuticals Plc, Key Competitors
  • Hikma Pharmaceuticals Plc, Ratios based on current share price
  • Hikma Pharmaceuticals Plc, Annual Ratios
  • Hikma Pharmaceuticals Plc, Annual Ratios
  • Hikma Pharmaceuticals Plc, Annual Ratios
  • Hikma Pharmaceuticals Plc, Interim Ratios
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Hikma Pharmaceuticals Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Hikma Pharmaceuticals Plc, Performance Chart (2013 - 2017)
  • Hikma Pharmaceuticals Plc, Ratio Charts
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Novartis Pharmaceuticals UK Ltd
  • Napp Pharmaceuticals Ltd
  • Lannett Company Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll